arGEN-X « Terug naar discussie overzicht

arGEN-X Nieuws 2017

568 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 ... 25 26 27 28 29 » | Laatste
de tuinman
1
quote:

yearling schreef op 26 oktober 2017 09:29:


Tuinman, dit lijkt me nieuws, inderdaad, dat de 'recruiting' van Phase 2 voor ARGX-113 MG afgerond is. Ik heb het nog niet eerder gelezen in ieder geval. Laatste verwijzing op de website vd link die jij post, is een update van 8 september, en toen was de 'enrolling' nog bezig. Dus lijkt het me dat het afronden van de recrutering nog heel recent is.


clinicaltrials.gov/ct2/show/NCT029655...

Aangepast.
de tuinman
0
Beetje dubbel.
Waarom zijn ze hier niet gelijk mee begonnen?
Aan de andere kant blijven ze nieuwe studies starten en hebben dus vertrouwen in het product.
Ze hebben vast wel al een indruk gekregen of de 1e poc geslaagd is of niet.
[verwijderd]
0
quote:

de tuinman schreef op 30 oktober 2017 11:32:


Beetje dubbel.
Waarom zijn ze hier niet gelijk mee begonnen?
Aan de andere kant blijven ze nieuwe studies starten en hebben dus vertrouwen in het product.
Ze hebben vast wel al een indruk gekregen of de 1e poc geslaagd is of niet.


Niet dubbel . Gewoon meer mogelijkheden . Deze onderzoeken kosten tijd . Bij Argen-X gaat de op/uitbouw razend snel .
Wat je al schrijft . Ze moeten op de 1 of andere manier al iets meer weten over ARGN-113 . Aangezien ze al zoveel studies uitvoeren in deze molecule .
Wat denk je wat er gebeurd als blijkt dat MG werkt en een studie MS gestart gaat worden . Hier zijn in het geheel nog geen goede medicijnen voor . Vasthouden LT !
de tuinman
0
Mooi instapmoment. Gaat alleen nog niet lukken.
Net nog een mail naar de bank gestuurd.
Ik ben benieuwd naar het antwoord.
harvester
0
quote:

de tuinman schreef op 31 oktober 2017 17:57:


Mooi instapmoment. Gaat alleen nog niet lukken.
Net nog een mail naar de bank gestuurd.
Ik ben benieuwd naar het antwoord.


Bij Binck lukte het mij wel.
de tuinman
0
quote:

harvester schreef op 1 november 2017 15:01:


[...]

Bij Binck lukte het mij wel.


Goed om te weten. Ik ga maar eens kijken of ik ga overstappen.
harvester
0
quote:

de tuinman schreef op 1 november 2017 17:58:


[...]

Goed om te weten. Ik ga maar eens kijken of ik ga overstappen.



Is best makkelijk Heb het jaren geleden gedaan toen de Rabo mij meldde dat ik Morphosys niet meer kon aanhouden in mijn Rabo effectenportefeuille. Dus opende in een effecten rekening bij Binck en liet de Morphosys aandelen overzetten. Kennelijk moeten banken per effect regel betalen en waren er te weinig RABO klanten in Morpho geïnteresseerd om dat rendabel te maken.
nelis h
0
tuinman, de Giro kun je geheel online regelen, zonder formulieren invullen en opsturen
[verwijderd]
0
Published: 07:00 CET 02-11-2017 /GlobeNewswire /Source: argenx SE / : ARGX /ISIN: NL0010832176

argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017




November 2, 2017



Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will host a key opinion leader (KOL) breakfast meeting focused on the potential of ARGX-113 to treat patients with pemphigus vulgaris (PV) on Friday, November 10, 2017 from 8:30 a.m. to 10:30 a.m. ET in New York.



The event will feature guest speaker Dr. John Stanley, M.D., University of Pennsylvania School of Medicine, who will highlight the treatment landscape and unmet need in PV. Additionally, members of argenx management will present details, including trial design, of the newly initiated Phase 2 ARGX-113 study in PV.



A live webcast of the event will be available via this link. The webcast will be archived following the event and available for download on the Company's website at www.argenx.com.



About argenx

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.

www.argenx.com


For further information, please contact:

Joke Comijn, Corporate Communications Manager

+32 (0)477 77 29 44

+32 (0)9 310 34 19

info@argenx.com

de tuinman
0
quote:

harvester schreef op 1 november 2017 20:44:


[...]

Is best makkelijk Heb het jaren geleden gedaan toen de Rabo mij meldde dat ik Morphosys niet meer kon aanhouden in mijn Rabo effectenportefeuille. Dus opende in een effecten rekening bij Binck en liet de Morphosys aandelen overzetten. Kennelijk moeten banken per effect regel betalen en waren er te weinig RABO klanten in Morpho geïnteresseerd om dat rendabel te maken.


Sorry voor off-topic.
Ik heb inderdaad ook even naar Mor gekeken en maar laten gaan, omdat deze niet in 'de lijst' stond.
Maar nu loop ik er weer tegenaan en het begint me nu serieus te irriteren.

Ik heb al de nodige info opgehaald, maar ik vind het ergens wel spannend om over te stappen, aangezien ik altijd bij 'good old' Rabo heb gezeten.
Maar ik begrijp dat jij (en anderen) geen moment spijt hebben gehad om over te stappen naar Binck?

nelis h
1
tuinman, Rabo hou je gewoon aan. de Giro en/of Binck neem je erbij.

Binck, wat hogere transactiekosten maar een prachtige site. Geld overboeken met een betaalopdracht, staat de volgende dag op de Binck rekening

de Giro, eenvoudig online rekening aanvragen, Geld overboeken snel via ideal.
Site vind ik wat minder dan Binck, wel lage transactiekosten.

gewoon doen, kunnen we dit punt afsluiten :)

de tuinman
0
Ik hoef niet per se de goedkoopste. Ik denk dat het Binck word. Vandaag nog even naar kijken.

Hoeki
0
Ben net ingestapt op 19,95. Nu wachten op de MG resultaten...

Mooie toevoeging aan mijn biotechaandelen Ablynx, Galapagos, Merus en een speculatief plukje Probiodrug.
Brammeke
0
Press Releases« BackPrinter Friendly Version View printer-friendly versionargenx announces results of extraordinary shareholders' meeting 2017November 7, 2017Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that all resolutions presented at the Company's extraordinary shareholders' meeting were duly passed at the meeting, which was held today at 09:00 CET.All proposed resolutions on the agenda for this extraordinary shareholders' meeting were approved. The results of the votes will be posted shortly on the Company's website and are summarized below: update of the remuneration policy taking into account the further development and evolution of the Companyrenewal of the authorization of the board of directors to issue shares up to a maximum of 20% of the outstanding share capital, with the authority to limit or exclude pre-emptive rights regarding an issuance of new shares.All documents relating to the extraordinary shareholders' meeting can be consulted on our website of the Company: www.argenx.comAbout argenxargenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. www.argenx.com For further information, please contact: Joke Comijn, Corporate Communications Manager+32 (0)477 77 29 44+32 (0)9 310 34 19info@argenx.comBeth DelGiacco (US IR)Stern Investor Relations+1 212 362 1200beth@sternir.comForward-looking StatementsThe contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should," and include statements argenx makes concerning the intended results of its strategy; its financial condition, results of operation and business outlook; the sufficiency of its cash, cash equivalents and current financial assets; and the momentum of its product candidate pipeline as well as the advancement of, and anticipated clinical development and regulatory milestones and plans related to, and data readouts for, argenx's product candidates and preclinical and clinical trials. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including argenx's expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates; argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in the final prospectus related to argenx's initial U.S. public offering filed with the SEC pursuant to Rule 424(b) of the Securities Act of 1933, as amended, as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.
de tuinman
0
quote:

bioscience schreef op 2 november 2017 11:57:


Published: 07:00 CET 02-11-2017 /GlobeNewswire /Source: argenx SE / : ARGX /ISIN: NL0010832176

argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017




November 2, 2017



Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will host a key opinion leader (KOL) breakfast meeting focused on the potential of ARGX-113 to treat patients with pemphigus vulgaris (PV) on Friday, November 10, 2017 from 8:30 a.m. to 10:30 a.m. ET in New York.



The event will feature guest speaker Dr. John Stanley, M.D., University of Pennsylvania School of Medicine, who will highlight the treatment landscape and unmet need in PV. Additionally, members of argenx management will present details, including trial design, of the newly initiated Phase 2 ARGX-113 study in PV.



A live webcast of the event will be available via this link. The webcast will be archived following the event and available for download on the Company's website at www.argenx.com.



About argenx

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.

www.argenx.com


For further information, please contact:

Joke Comijn, Corporate Communications Manager

+32 (0)477 77 29 44

+32 (0)9 310 34 19

info@argenx.com




Spannend. Ik kan mij eigenlijk niet voorstellen dat Argenx op deze manier gaat vertellen dat de studie een mislukking is.
Maar het lijkt mij niet dat ze nu al met uitgebreide resultaten gaan komen.
568 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 ... 25 26 27 28 29 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 25 jan 2022 15:00
Koers 228,700
Verschil -4,100 (-1,76%)
Hoog 235,200
Laag 227,300
Volume 29.272
Volume gemiddeld 67.362
Volume gisteren 105.106